News from Eisai Inc. A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages.

Latest

Mar 28, 2017, 07:55 ET Eisai to Present Clinical and Preclinical Research from Oncology Portfolio at 2017 AACR Annual Meeting

Eisai Inc. announced today 13 presentations of clinical and preclinical research at the American Association for Cancer Research (AACR) 2017 Annual...


Mar 23, 2017, 08:06 ET Eisai to Launch New Medikidz Epilepsy Comic Book at the National Walk for Epilepsy

Eisai Inc. is pleased to announce that it will be launching the latest "Medikidz Explain Epilepsy," book as part of their participation at the...


Mar 17, 2017, 08:00 ET Dr. Kirk Shepard appointed Senior Vice President, Global Medical Affairs of the Oncology Business Group at Eisai Inc.

Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., today announced the immediate appointment of Kirk Shepard, MD, as Senior Vice...


Jan 25, 2017, 08:00 ET Positive Topline Results of Large Phase 3 Trial Show Eisai's Lenvatinib Meets Primary Endpoint in Unresectable Hepatocellular Carcinoma

Eisai Inc. today announced positive topline results from the randomized, multicenter Phase 3 trial (Study 304) evaluating the company's multiple...


Jan 18, 2017, 08:00 ET Eisai to Participate in Access Accelerated, Global Partnership to Address Rise of Non-Communicable Diseases

Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., announced today that it is participating in Access Accelerated, a global...


Jan 04, 2017, 16:05 ET Eisai Acquires All Global Development And Marketing Rights For Chronic Weight Management Treatment Lorcaserin HCI

Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd. (collectively, "Eisai"), announced today that it has reached an agreement with...


Dec 19, 2016, 13:30 ET Eisai and Arena Pharmaceuticals Announce Regulatory Approval of BELVIQ® (lorcaserin HCl) in Brazil

Eisai Inc. and Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced that Eisai Laboratórios Ltda., a subsidiary of Eisai Inc., has...


Dec 12, 2016, 08:06 ET Eisai Presents Data on BACE Inhibitor Elenbecestat (E2609) at 9th Clinical Trials on Alzheimer's Disease (CTAD) Meeting

Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., announced today the presentation of two posters highlighting the latest...


Dec 05, 2016, 13:00 ET Eisai Announces Final Results from Phase 3 Open-Label Study of Rufinamide at American Epilepsy Society (AES) Annual Meeting

Eisai Inc. announced today final results of its Phase 3 open-label two-year study of rufinamide, which were presented at the 2016 Annual Meeting of...


Dec 05, 2016, 13:00 ET Eisai Announces New Analyses and Data on Perampanel at American Epilepsy Society (AES) Meeting

Eisai Inc. announced today new analyses and data on perampanel presented at the 2016 Annual Meeting of the American Epilepsy Society (AES)....


Dec 01, 2016, 08:00 ET Rebecca Jolley appointed Senior Vice President Americas Commercial, Oncology Business Group at Eisai Inc.

Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., today announced the immediate appointment of Rebecca Jolley as Senior Vice...


Nov 30, 2016, 11:39 ET New Data on Eribulin Mesylate Injection to Be Presented at the 2016 San Antonio Breast Cancer Symposium Explore Potential of Regimens in Treatment of Metastatic Breast Cancer

Eisai Inc. announced today the presentation of new data from studies of eribulin, marketed under the brand name Halaven®, at the 2016 San...


Nov 28, 2016, 09:41 ET New Data and Analyses on FYCOMPA and BANZEL at American Epilepsy Society Meeting Demonstrate Eisai's Continued Commitment to the Epilepsy Community

Eisai Inc. announced today the presentation of 12 posters during the 70th annual American Epilepsy Society (AES) Annual Meeting, highlighting data...


Nov 17, 2016, 09:05 ET FDA Grants Fast Track Designation for Development of E2609, Eisai's BACE Inhibitor for Early Alzheimer's Disease

Eisai Inc. announced today that it has received U.S. Food and Drug Administration (FDA) Fast Track designation for the development of E2609, a...


Nov 03, 2016, 08:05 ET Eisai and Arena Pharmaceuticals Announce Presentation of BELVIQ® (lorcaserin HCl) Data at 2016 Annual Obesity Week Meeting

Eisai Inc. and Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today the presentation of one oral presentation and one poster at Obesity...


Oct 31, 2016, 08:10 ET Eisai Initiates Phase 2 Clinical Trial to Evaluate Lemborexant in the Treatment of Irregular Sleep-Wake Rhythm Disorder (ISWRD) in Dementia Patients

Eisai Inc. and Purdue Pharma L.P. announced today the initiation of a multi-center, randomized Phase 2 clinical study (Study 202) to evaluate...


Oct 31, 2016, 08:05 ET Now Enrolling: Global Phase 3 Clinical Study to Evaluate Eisai's BACE Inhibitor in Early Alzheimer's Disease

Eisai Inc. announced today that enrollment has begun in the U.S. for MISSIONAD, a Phase 3 clinical program for E2609, a Beta-secretase Cleaving...


Oct 28, 2016, 09:05 ET Eisai Announces Initiation of Two Phase 3 Clinical Trials with FYCOMPA® (perampanel)

Eisai Inc. announced today the initiation of two multi-center, global Phase 3 clinical trials assessing FYCOMPA® (perampanel) CIII in two different...


Oct 26, 2016, 14:27 ET Eisai's LENVIMA® (lenvatinib) Nominated for Galien Foundation's Best Pharmaceutical Product

Eisai Inc. announced today that LENVIMA® (lenvatinib), the company's multiple receptor tyrosine kinase inhibitor (TKI), has been nominated for Best...


Oct 26, 2016, 08:10 ET Eisai Launches New Medikidz Epilepsy Comic Book in Conjunction with Lennox-Gastaut Syndrome (LGS) Awareness Day

Eisai Inc. today announced the launch of "Medikidz Explain Lennox-Gastaut Syndrome (LGS)," an educational comic book designed to inform people...


Oct 13, 2016, 19:22 ET Preliminary Results from Lenvatinib + Pembrolizumab Phase 1b Clinical Study in Select Solid Tumors Presented at ESMO 2016

Eisai Inc. announced today the presentation of preliminary results of a Phase 1b clinical study (Study 111) of its in-house developed multiple...


Oct 03, 2016, 08:06 ET Eisai Inc. and Arena Pharmaceuticals Announce Availability of Once-Daily BELVIQ XR® (lorcaserin HCl) Extended-Release Tablets

 Eisai Inc. and Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced the availability of BELVIQ XR® (lorcaserin HCl) CIV...


Sep 29, 2016, 08:30 ET New Halaven® (eribulin) and Lenvima® (lenvatinib) Data to be Presented at ESMO Demonstrate Continued Commitment to Eisai Oncology Portfolio

 Eisai Inc. announced today the presentation of seven abstracts featuring data on its cancer treatments at the European Society of Medical...


Sep 29, 2016, 07:30 ET Now Enrolling: Global Phase 3 Clinical Trial to Evaluate Potential First-Line Use of Lenvatinib in Combination with Pembrolizumab or Everolimus for Patients with Advanced Renal Cell Carcinoma

 Eisai Inc. announced today the initiation of a multicenter, global, randomized Phase 3 study that will evaluate the efficacy and safety of two...